Every figure this model derived for BIOE, the value it took, and
the element in the company's own XBRL it was read from — so any of it can be checked
against the filing rather than taken on trust.
As at 2026-06-30.
The figures, and where each came from
This is the part no other screener shows. Each figure below names the XBRL element it
was read from, so it can be checked against the filing itself.
The figures themselves rather than their scores — what somebody looking up
BIOE on one particular measure came for.
Ratio
Value
cash operating margin
56.42
current ratio
0.38
current ratio reported
0.38
dilution pct
0.0
fcf margin
36.95
growth cv
2.57
interest cover
2186.03
net debt ebitda
0.03
operating margin
52.86
owner earnings margin
36.95
revenue growth
416.63
revenue growth per share
416.63
roic
50.68
rule of 40
469.49
sbc pct revenue
0.0
What to be careful about
What this model itself distrusts about BIOE's figures. Written by the
derivation as it ran, not added afterwards.
no current stock compensation tagged (last tagged 2020-12-31); treated as zero, so owner earnings are overstated
no current capital expenditure tagged (last tagged 2023-12-31); treated as zero, so free cash flow is overstated and equals operating cash flow
no market cap; set `market_cap` in overrides.yaml
no forward EPS estimate; growth rests on filings only. Analyst consensus is not published in XBRL, so it has to be fetched from a data provider or set by hand in overrides.yaml as `eps_growth_2y`
valuation DROPPED from the total: only 0 of 2 inputs could be computed (ev sales, ev owner earnings not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
durability rests on 3 of 4 inputs; not tagged: contracted coverage